Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

Autor: Cristina Rivas Juesas, Montserrat Bosque, Luz Martínez Pardo, Mercedes Sánchez Mateos, Alfredo Valenzuela Soria, Miguel Tortajada, Ángel Mazón Ramos, A.M. Plaza, María Nieto Cid, Genoveva del Río Camacho, José Batlles Garrido, Esther Ballester Asensio, Antonio Nieto Garcia, Raquel Romero, Teresa Garriga-Baraut, Elena Vázquez Rodríguez, María Penín Antón, Laura Valdesoiro Navarrete, María Araceli Caballero-Rabasco, Jaime Lozano, Verónica Sanz Santiago, E. Alonso, Alejandro López Neyra, Carmen Aragón Fernández, M M Folque, Juan Navarro Morón, A. Andrés Martín, Álvaro Gimeno Díaz de Atauri, Javier Torres-Borrego, Laura Moreno-Galarraga, Andrea Freixa, Mirella Gaboli
Rok vydání: 2021
Předmět:
severe asthma
medicine.medical_specialty
Pediatrics
Immunology
real life
Omalizumab
humanized monoclonal antibodies
adolescents
Antibodies
Monoclonal
Humanized
Anti-asthmatic Agent
03 medical and health sciences
0302 clinical medicine
children
Internal medicine
medicine
anti-asthmatic agents
Humans
Immunology and Allergy
Children
adolescents
anti-asthmatic agents
humanized monoclonal antibodies
observational study
omalizumab
real-life
severe asthma
Anti-Asthmatic Agents
030212 general & internal medicine
Child
Adverse effect
Retrospective Studies
business.industry
asthmatic agents
observational study
anti‐
Retrospective cohort study
Asthma
Discontinuation
omalizumab
Treatment Outcome
Pulmonology
030228 respiratory system
Severe persistent allergic asthma
Pediatrics
Perinatology and Child Health
Cohort
Observational study
business
medicine.drug
Zdroj: PEDIATRIC ALLERGY AND IMMUNOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
ISSN: 1399-3038
0905-6157
DOI: 10.1111/pai.13484
Popis: BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients
Databáze: OpenAIRE
Externí odkaz: